

**Press release**

Lund 17 October 2022

# **Scandinavian ChemoTech's Animal Care division receives purchase order from FloridaWild Veterinary Hospital**

**Following up on the request for purchase which was communicated in August, FloridaWild has accepted the purchase of the already installed vetIQure™ after a successful evaluation.**

The continued joint goal is to establish FloridaWild as a "Centre of Excellence" to obtain and evaluate more clinical data for different animal species.

We are, along with FloridaWild, also having ongoing discussions with MVP – Mission Veterinary Partner – regarding installing the vetIQure™ device on other clinics within the organisation. MVP is a veterinary services organisation founded in 2017 and is a group of around 350 veterinary clinics and hospitals across the States.

*"We are happy to announce that today we received confirmation that FloridaWild will fulfil their commitment to purchase the vetIQure™ device after a six-month clinical service agreement. We are delighted to have FloridaWild as part of our collaboration in testing the efficacy of TSE and assisting in the growth process of expanding our technology across North America." - says Danny Edward Nesrallah, Head of Business Development North America for Vetique AB*

*"We have been very impressed with our patient outcomes over the last 6 months and are pleased to be able to permanently provide our patients access to this therapy. We have also been pleased with the support we continue to get from Danny Nesrallah and his team, as they unfailingly provide any medical or technical support we require. Vetique has been a partner in ensuring ethical patient selection and thorough data collection, which solidifies my faith in this company and its commitment to research and improving cancer care. We are pleased to have their support as we provide this therapy and proud to play a role in contributing to their work." - says Dr Pamela Schrager, Medical Director, FloridaWild Veterinary Hospital*

*For more information, please contact:*

Mohan Frick, CEO

+46 (0)10-218 93 00

[ir@chemotech.se](mailto:ir@chemotech.se)

**Certified Adviser: Erik Penser Bank, Tel: Corporate Finance AB, Tel: +46 8-463 80 00, E-mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)**

### **Scandinavian ChemoTech AB (publ)**

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: [www.chemotech.se](http://www.chemotech.se).